POS0222 EFFICACY AND SAFETY OF AVACOPAN IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS RECEIVING RITUXI...
POS0222 EFFICACY AND SAFETY OF AVACOPAN IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS RECEIVING RITUXIMAB IN THE ADVOCATE TRIAL
About this item
Full title
Author / Creator
Geetha, D. , Dua, A. , Yue, H. , Salvarani, C. , Jayne, D. and Merkel, P.A.
Publisher
Kidlington: Elsevier B.V
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: Elsevier B.V
Subjects
More information
Scope and Contents
Contents
The randomized, double-blind, double-dummy, controlled Phase 3 ADVOCATE trial tested whether avacopan, an oral selective C5a receptor inhibitor approved for the treatment of ANCA-associated vasculitis (AAV), could replace a glucocorticoid (GC)-tapering regimen. Randomization was stratified according to vasculitis disease status (newly diagnosed or...
Alternative Titles
Full title
POS0222 EFFICACY AND SAFETY OF AVACOPAN IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS RECEIVING RITUXIMAB IN THE ADVOCATE TRIAL
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2860486020
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2860486020
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2023-eular.1447
